Last reviewed 2026-06-01 · How we verify

Deucrictibant high dose

Pharvaris Netherlands B.V. · Phase 2 active Small molecule Under review

Deucrictibant high dose is a Bradykinin receptor antagonist Small molecule drug developed by Pharvaris Netherlands B.V.. It is currently in Phase 2 development for Hypertension.

Deucrictibant is a bradykinin receptor 2 antagonist.

Deucrictibant is a small molecule used to treat Hereditary Angioedema, specifically in the acute treatment of angioedema attacks in patients with Hereditary Angioedema. It is administered orally as part of a Phase II/III extension study.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Deucrictibant high dose
Sponsor	Pharvaris Netherlands B.V.
Drug class	Bradykinin receptor antagonist
Target	B2 receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Deucrictibant works by blocking the action of bradykinin at its receptor, which is involved in blood pressure regulation. This leads to vasodilation and a decrease in blood pressure. Deucrictibant is being investigated for its potential to treat hypertension.

Approved indications

Hypertension

Common side effects

Hypotension

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Deucrictibant high dose CI brief — competitive landscape report
Deucrictibant high dose updates RSS · CI watch RSS
Pharvaris Netherlands B.V. portfolio CI

Frequently asked questions about Deucrictibant high dose

What is Deucrictibant high dose?

Deucrictibant high dose is a Bradykinin receptor antagonist drug developed by Pharvaris Netherlands B.V., indicated for Hypertension.

How does Deucrictibant high dose work?

Deucrictibant is a bradykinin receptor 2 antagonist.

What is Deucrictibant high dose used for?

Deucrictibant high dose is indicated for Hypertension.

Who makes Deucrictibant high dose?

Deucrictibant high dose is developed by Pharvaris Netherlands B.V. (see full Pharvaris Netherlands B.V. pipeline at /company/pharvaris-netherlands-b-v).

What drug class is Deucrictibant high dose in?

Deucrictibant high dose belongs to the Bradykinin receptor antagonist class. See all Bradykinin receptor antagonist drugs at /class/bradykinin-receptor-antagonist.

What development phase is Deucrictibant high dose in?

Deucrictibant high dose is in Phase 2.

What are the side effects of Deucrictibant high dose?

Common side effects of Deucrictibant high dose include Hypotension.

What does Deucrictibant high dose target?

Deucrictibant high dose targets B2 receptor and is a Bradykinin receptor antagonist.

Drug class: All Bradykinin receptor antagonist drugs
Target: All drugs targeting B2 receptor
Manufacturer: Pharvaris Netherlands B.V. — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing